Cohort | Combined | ||||||
Côte d’Ivoire (Abidjan) | Uganda (Masaka) | Uganda (Rakai) | Thailand (Royal Thai Army) | Thailand (Chiang Mai) | |||
Reference | Minga et al9 | Morgan et al32 | Wawer et al33 | Rangsin et al12 | Nagachinta et al13 | – | |
Study population | Blood donors | Participants in community cohort | Participants in community cohort | Military conscripts | Male blood donors and their female partners | – | |
Year of start of study | 1997 | 1990 | 1991 | 1998 | 1992 | ||
No of participants included in analyses (%) | 253 (100) | 338 (100) | 411 (100) | 233 (100) | 837 (100) | 2072 (100) | |
Median (IQR) interval between last negative and first positive HIV-1 test, months | 7.5 (3.4–19.1) | 12.5 (11.7–24.3) | 22.4 (14.6–37.7) | 8.5 (5.7–9.5) | 50.7 (31.6–69.8) | 24.0 (11.8–50.1) | |
No of women (%) | 97 (38.3) | 180 (53.2) | 256 (62.3) | 0 (0) | 267 (31.9) | 800 (38.6) | |
No of patients starting ART (%) | 79 (31.2) | 57 (16.9) | 151 (36.7) | 0 (0) | 0 (0) | 287 (13.8) | |
Mean (SD) age at baseline, years | 29.1 (7.1) | 32.0 (13.6) | 35.8 (2.5) | 22.1 (0.9) | 28.7 (6.4) | 29.9 (8.3) | |
Median (IQR) baseline CD4 cell count (IQR), cells ×106/l | 472 (331–648) | 553 (425–743) | 409 (235–584) | NA | NA | – | |
Median (IQR) number of CD4 counts per person | 9 (5–14) | 5 (2–11) | 3 (2–7) | NA | NA | – | |
Median (IQR) follow up from seroconversion, years | 5.4 (5.4–7.6) | 4.9 (3.3–7.8) | 5.7 (3.8–7.6) | 6.0 (5.3–6.7) | 6.5 (5.2–9.1) | 6.0 (4.4–7.8) |
NA, not systematically assessed and therefore not analysed in this study; SD, standard deviation; IQR, interquartile range.
The baseline CD4 count relates to the first measurement after seroconversion.